Fairscale Capital’s GSK GSK Stock Holding History

Fairscale Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,239	Closed	-$54K	–	442
2025 Q3	$54K	Hold	1,239	–	–	0.04%	188
2025 Q2	$46K	Buy	+1,239	New	+$47.3K	0.03%	195

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fairscale Capital's GSK Position: Q4 2025 in Review

Fairscale Capital sold out of GSK (GSK) in Q4 2025, closing a stake of 1,239 shares — an estimated $54K sold.

Fairscale Capital first reported a position in GSK in Q2 2025 and held it in 2 quarters. The position peaked at $54K in Q3 2025. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Fairscale Capital reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Fairscale Capital sold 1,239 GSK shares in Q4 2025, an estimated $54K.
Fairscale Capital first reported a position in GSK in Q2 2025 and held it in 2 quarters.
Fairscale Capital's GSK position peaked at $54K in Q3 2025.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Fairscale Capital's 13F filing for Q4 2025, filed 17 Feb 2026.